Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin bioequivalence study in healthy males
NCT07156916Phase 1Recruiting
- Sponsor
- Menarini Group
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Menarini Group. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration at 72 hours and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07156916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156916.